What is the optimal combination of lipid-lowering treatments or achieved LDL-C level that will result in the largest reduction in CV events?
The optimal combination of lipid-lowering treatments or achieved LDL-C level that will result in the largest reduction in CV events is not yet known. The Work Group suggests that in patients at higher risk (see Recommendation 12 for a definition) who are already receiving a maximally tolerated statin plus ezetimibe, the addition of a PCSK9 inhibitor is suggested to reduce recurrent non-fatal events. More research is needed to determine the long-term safety of treatment with PCSK9 inhibitors combined with statins with or without ezetimibe, and the unknown safety of prolonged periods of very low LDL-C levels secondary to this treatment.